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TUTORIAL

How to Conduct Clinical Trials in Children: A Tutorial
Valentina Shakhnovich1,2,*, Christoph P. Hornik3, Gregory L. Kearns4, Jaylene Weigel1 and Susan M. Abdel-Rahman1,2

Despite a growing interest in, and commitment to, implementing pediatric clinical trials, approximately one in every five trials
in children fails because of inappropriate study design, suboptimal experiment planning, or inadequate participant enrollment. This tutorial, presented from the perspectives of seasoned pediatric investigators, an experienced research coordinator, and an established pediatric clinical trials network, is designed to provide practical guidance for successfully implementing
pediatric clinical trials at an academic center or another comparable institution.
The evolution in pediatric legislation (Figure 1),1 a growing
commitment to pediatric studies by the pharmaceutical industry, and a renewed interest in therapeutics for rare diseases have increased the demand for timely, high-quality,
cost-effective clinical trials in children.2,3 Despite the urgency and the implementation of incentives to conduct
these trials, approximately one in every five pediatric trials
fails because of inappropriate study design, suboptimal experiment planning, or inadequate participant enrollment.4,5
This tutorial, presented from the perspectives of seasoned
pediatric investigators, an experienced research coordinator, and an established pediatric clinical trials network, is
designed to provide practical guidance for successfully implementing pediatric clinical trials at your institution.
PLANNING YOUR STUDY
Easily recognizable as problematic, to an experienced pediatric clinical trialist, are sponsored protocols intended
for children that are virtually indistinguishable from the
antecedent adult trials. This singular protocol feature is
assured to present challenges in the execution of the trial
and interpretation of the study data.5 A successful pediatric
trial, by contrast, takes into consideration the influence of
normal growth and development on physiologic processes
that are relevant to medication administration, drug disposition, the measurement of drug response, and how the
intersection of development and disease impact both the
logistical and scientific aspects of the study.6,7
Medication administration
In a population where items intended for oral ingestion, including foods and medicines, are often rejected on the basis
of smell, taste, and texture, the importance of drug formulation cannot be overemphasized. Consistent, reliable drug
delivery during a clinical trial necessitates age-appropriate
formulations. Although stable and easy to transport, solid
oral dosage forms can be difficult for young children to
manage. Importantly, these formulations limit the extent to
which the dose can be titrated in a population of individuals
1

with widely disparate weights (e.g., below 500 g for some
neonates8 and well in excess of 100 kg for some adolescents9). Minitablets, chewables, orodispersibles, and liquid
formulations can, to varying extent, overcome the challenges of accurate weight-based dosing; however, these
formulations can be rejected as a result of their texture,
taste, or smell, each of which has a unique developmental
trajectory, driven by teleology and overlaid by adaptive and
cultural influences.10,11
Allowing more than one formulation within a study
can broaden the range of children eligible for participation, but can introduce unexpected challenges. We recall
a sponsored study incorporating both a solid and liquid
formulation, where the latter was so poorly formulated
that vomiting rates approached 25% (vs. 0% for the solid
formulation).5 Fortunately, in this single-dose pharmacokinetic (PK) trial, withdrawn participants could be replaced,
albeit at an expense in excess of what was initially budgeted in the study. Had this study required repeated dose
administration, the result could very well have been failure
of the trial.
Using a single adult formulation, or permitting extemporaneous compounding of an adult formulation
to accommodate children, can reveal a different set of
challenges, and the impact of formulation may not become apparent until the time of data analysis. We have
encountered clinical trials in which extemporaneous compounds were made to the wrong specifications, resulting
in plasma concentrations that were below the lower limit
of detection. We also have examples of trials in which
the process of compounding interfered with delivery of
the active compound, such that we were unable to disentangle formulation effects from age effects at the time
of data analysis.5 Ultimately, the decision to make a provision for compounding in your protocol should not be
undertaken without consideration for the frequency with
which the preparation will need to be made, whether quality control measures can be put in place, and whether this
approach is suitable for the study’s medication administration strategy.
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Figure 1 Evolution in pediatric drug legislature; image created with content from Tolbert et al.1 FDA, US Food and Drug Administration.

With respect to extemporaneous preparation, we have
also observed trials in which existing dosage forms were
modified, and co-administered foods/beverages interfered
with the bioavailability of the active drug compound, resulting in unexpected disposition profiles and, in some cases,
failure to satisfy bioequivalence criteria.7 Through Figure 2,
derived from a study in healthy volunteers, we illustrate the
impact of a pediatric dietary staple (apple juice) on the systemic exposure to a medication.12 Prior to our improved
understanding of the impact of drug–nutrient interactions
on presystemic drug metabolism and transport, it was not
uncommon to encounter pediatric trials permitting concomitant juice administration, and we still see studies that permit
flavored beverages (e.g., fruit punch), despite the fact that
most contain apple juice as an ingredient. Failure to recognize or account for the effect of food and formulation during

data capture can introduce added levels of variability, confounding data interpretation and experimental results.
Dosing approach
Considerations surrounding medication administration
also extend to the dosing approach. Pediatric trials are
frequently conducted after the exposure–
response relationship for the drug of interest has been determined in
adults,5 with adult data informing reference ranges for dose
selection in children. To account for variability in size across
the age spectrum, drug doses can be normalized to body
mass (mg/kg), lean body mass (mg/kg lean body weight
or fat-free mass), or surface area (mg/m2) to approximate
weight-
adjusted exposures in adults. These approaches
are particularly useful when existing data offer support for
a comparable pharmacodynamics (PD) profile between
www.cts-journal.com
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Figure 2 Mean plasma concentrations (means ± SD) of
fexofenadine (FEX) after oral administration of FEX 60 mg
with water 600 mL, apple juice (AJ) 150 mL, followed by water
450 mL, AJ 300 mL, followed by water 300 mL, and AJ 600 mL.
N = 10; image adapted from Luo et al.,12 https://doi.org/10.1111/
cts.12400, is licensed under CC BY-
NC-
ND 4.0. ©2016 The
authors.

adults and children; however, they require an easily titratable drug formulation.
Alternatively, a fixed dose of a drug (mg) may be administered to subjects across the continuum of pediatric ages,
such that drug doses span a targeted range, when corrected
for body weight/size (e.g., mg/kg or mg/m2). Given the wide
range in body size encountered in the pediatric population,
the fixed-dose approach may result in significant variability
in weight-adjusted or size-adjusted drug exposures, which
will need to be addressed during data analysis. Ultimately,
the objective of the study, as well as the availability of an
age-appropriate drug formulation, should guide the dose
selection strategy for a pediatric investigation.
EXPERIMENTAL DESIGN
Knowledge of the impact of normal growth and development on drug disposition informs experimental design, as
it relates to PK and PD sampling schemes and assay sensitivity requirements. Although a thorough review of these
principles is outside the scope of this article, we provide
several illustrative examples below.
Drug disposition
For orally administered medications, physiologic changes
in the gastrointestinal tract need to be considered when
designing a pediatric study spanning different age groups.
The relative achlorhydria during the neonatal period, for
example, can protect acid labile drugs, resulting in higher
systemic concentrations after oral administration relative to
older children and adults.13 Conversely, weakly basic drugs
may experience reduced bioavailability at these higher
gastric pH values.14 Maturation of gastric emptying and
intestinal motility, during the first few weeks15 to years7 of
life, correspond with decreased times to reach maximum
blood concentrations for many drugs (e.g., cisapride8) for
the younger pediatric age range. Similarly, for drugs that
require bile salts to facilitate uptake, absorption may be erratic and incomplete during the first few months of life,16,17
Clinical and Translational Science

secondary to the immaturity of transporters responsible for
carrying them across the biliary canaliculi.18–22
The gastrointestinal tract has other important features
that influence the bioavailability of orally administered medications, including phase I and II drug-metabolizing enzymes
and drug transporters. Although data on the intestinal expression of these proteins are sparse,23–27 existing data
merit consideration. Reduced bioavailability, due to drug-
metabolizing enzyme ontogeny, can lead to samples that
fall below the lower limit of quantification at the end of the
sampling interval. Too few values on the terminal slope can
compromise half-life and area under the concentration–time
curve (AUC) estimates. By extension, enhanced absorption
can result in concentrations that exceed the upper limit of
quantification when the working concentration range for
the bioanalytical method does not span several orders of
magnitude, requiring reanalysis, assuming sufficient residual
sample remains. Alterations in gastric emptying and intestinal transit may require changes to sampling strategy, such
that data-rich segments of the PK profile are modified to
enable adequate characterization of both the apparent time
to peak concentration (Tmax) and the peak plasma concentration (Cmax).
As total and free circulating drug concentrations relate to
apparent distribution volume, it is equally important to recognize that total body water stores in children are increased
compared with adults, effectively lowering drug concentrations of hydrophilic drugs.10 The extent of protein binding
can also be reduced, primarily in young infants, owing to
higher concentrations of endogenous substances capable
of binding albumin (e.g., bilirubin, fatty acids), lower α1-
acid glycoprotein concentrations, and albumin stores that
are constituted, in part, by fetal albumin, which has a lower
binding affinity for drugs.28,29 The impact of these changes
on moderately bound drugs are likely limited; however, for a
highly protein-bound drug, a small shift in binding may significantly increase the unbound concentration of drug available to interact with therapeutic targets, depending on the
hepatic extraction ratio and apparent distribution volume of
the drug.
Disposition can also be altered for drugs administered via
extraoral routes. Enhanced percutaneous absorption can
be expected in children, owing to a larger surface area, improved hydration status, and increased capillary perfusion
of the skin.10 Because of erratic lower colonic contractions,
rectal suppositories that are slower to melt may be expelled
in young infants before complete release of the drug, resulting in a lower fractional absorption.30
Sampling strategy
Ontogenic changes in the rate of drug elimination influence the extent of sampling required to characterize PK
and the timeframe over which to examine PD. Importantly,
drug clearance pathways mature at different rates; therefore, in designing a successful pediatric trial, one must explore whether the drug under investigation is a substrate
for proteins or elimination pathways that are maximally
expressed perinatally (e.g., cytochrome P450 (CYP)s 2C9,
2C19, and 3A7, and sulfotransferase 1A1 and 1E1), shortly
after birth (e.g., CYPs 2D6, glutathione S-
transferase
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Table 1 Average reference weights and volumes for children representing various age groups

Age

Weight (kg)

Normal daily fluid
requirement (mL)

Circulating blood volume
(mL)

Max allowable sample volume
over 2 weeks (mL)

Preterm neonate

1.5

144

120

3.6

Full-term neonate

4

384

144

9.6

Infant/toddler (3 years)

15

1,250

320

36

Child (12 years)

40

1,920

1,200

96

(GST)A1 and GSTA2), or at varying points during infancy
or childhood (e.g., CYPs 1A2, 2B6, 2C8, and 3A4/5, and
UDP-glucuronosyltransferases 1A1, 1A9, and 2B7, GST1,
glomerular filtration, and active tubular secretion).31 It is
also important to recognize whether redundancy exists (i.e.,
for polyfunctional substrates), such that ontogeny of compensatory pathways may be relevant.
Knowledge of the anticipated impact of developmental changes in clearance and distribution volume can and
should be used to inform your sampling strategy. Specific
attention should be paid to changes in clearance and volume that can occur in concert to intensify the developmental
effect. For example, our pediatric study of linezolid revealed
concentrations at the end of a 12-hour dosing interval that
were more than an order of magnitude lower than reported
in adults, secondary to an expanded distribution volume and
enhanced total body clearance.32
Overlaid on the developmental differences highlighted
above are acute or chronic pediatric diseases that can independently interfere with drug disposition. Gastric emptying
rates are influenced by pediatric comorbidities, including
prematurity, gastroesophageal reflux disease, congenital
heart disease, and type I diabetes.33 Intestinal dysmotility
accompanies gastroschisis, Hirschsprung’s disease, and
infantile pyloric stenosis.34–36 Children with amino acid
n-acyltransferase deficiency, or those receiving chronic total
parenteral nutrition, may experience alterations in protein
binding, whereas renal filtration is expected to be compromised in children with nephropathies, such as focal segmental glomerulosclerosis.10
For anticipated scenarios, such as those described
above, special consideration may need to be given to assay
sensitivity and specimen volumes. However, pediatric protocols must always remain cognizant of blood volume requirements defined by institutional review boards (IRBs). A
commonly overlooked flaw in sampling strategy involves
study protocol requirements that call for blood volumes exceeding the maximum allowable amounts for a given age
or size of a child. Although there is an inherent degree of
variability among IRBs, most stipulate that no more than 3%
of the estimated circulating blood volume may be removed
from a child, for research and clinical purposes combined,
over a specified period (typically 2–8 weeks).3,5 This can be
problematic and particularly restrictive for investigations in
preterm neonates, where typical total maximum allowable
volumes amount to < 5 mL (Table 1).5
Knowing the stipulations of your IRB with respect to
allowable blood volume is essential to successful protocol design. For example, some sampling constraints can
be overcome with sparse sampling schemes, scavenged

samples (i.e., those left over after medical procedures), or
population PK approaches.3,5 Similarly, careful evaluation of
the minimum amount of biological sample necessary for analytical integrity and close communication with the sample
processing laboratory can be incredibly valuable for reducing unnecessary sample collection and achieving a protocol
design that is acceptable to the investigator, the participant,
their parent/legal guardian, and the IRB.
Drug response
Physiologic alterations unique to the growing and developing child, as described above, may also influence PDs
and the selection of appropriate PD markers (usually,
drug safety and efficacy) for your investigation. Some PD
markers, like minimum inhibitory concentration for antimicrobial agents, can be extrapolated from adult studies. However, other “well-accepted” PD end points (e.g.,
exercise capacity measured by a 6-minute walk test) are
simply inappropriate for younger children, and pediatric
investigators have to rely on alternate markers of PD. Some
general guidance regarding appropriate biomarker selection and PD extrapolation can be gleaned from the US
Food and Drug Administration (FDA) 37 and the European
Medicines Agency (EMA);38,39 however, many knowledge
gaps remain for children,40 and it is the responsibility of
the pediatric investigator to consider natural variability in
PD end points across the pediatric age range. Cutoffs for
the upper limit of normal for commonly used screening
laboratories (e.g., hemoglobin and hematocrit), hepatic
safety parameters (e.g., aminotransferases and alkaline
phosphatase), and biomarkers of inflammation (e.g.,
erythrocyte sedimentation rate and C-reactive protein),
for example, all vary with the age of the child; therefore,
age-c orrected ranges should be used in the context of a
pediatric trial.
A popular strategy for measuring drug response that
facilitates PD comparison and extrapolation across studies is study end-point parameterization, in which markers
of response (e.g., disease severity) are turned into numeric
scores; however, few existing scores are validated for children.40 Investigators must remain cognizant of this shortcoming and, at times, be prepared to take on investigation
to validate a particular assessment tool to demonstrate its
utility for pediatric research. In order to be useful, assessment tools, especially ones that rely on self-report, need to
be age a
 ppropriate for nonverbal and preschool children if
these younger children are included in the targeted study
population. Similarly, monitoring devices for assessing PD
(e.g., blood pressure cuffs for an antihypertensive trial, otoscope tips for an otitis media trial) must be age appropriate
www.cts-journal.com
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and size a
ppropriate for the pediatric population under
investigation.
STUDY POPULATION
To some extent, the study population you choose will be
guided by the nature of the drug being studied and the target medical condition to which it applies. However, there are
nuanced considerations that need to be kept in mind when
designing a pediatric trial. For example, will study cohort
selection be guided by well-accepted, albeit arbitrary, age
ranges (e.g., neonate: 0–1 month; infant: 1 month–2 years;
child: 2–12 years; adolescent: 12–18 years) that may have
little bearing on the developmental trajectory of relevant
disposition/response pathways? When relying on these
categories, trialists should consider that physiologic differences within individual age categories can still contribute
substantially to variability in study results. Neonates, for
example, demonstrate striking differences in organ maturation depending on their gestational age.6 Organ function in this population is also affected by prenatal/perinatal
events (e.g., prenatal drug exposure, asphyxia at birth),
pathophysiologic conditions, and postnatal events (e.g.,
concomitant treatments). Similarly, variability in exposure–
response relationships within the adolescent population
is observed as a consequence of body composition, pubertal status, and circulating hormone profiles.6 Failure to
account for the extent of intersubject variability, contributed by these factors, may result in study sample size that
compromises the statistical power of the investigation, and
some investigators may choose to base study cohorts on
maturity ratings, like Tanner Staging, rather than age for
this reason.
Apart from the variability contributed by growth and development to individual age groups, consideration should
also be given to differences in the prevalence and/or etiology of disease across the range of cohorts intended for
the protocol. For example, a study designed to assess the
influence of age on the disposition of an oral antihypertensive agent may be difficult to perform, given that essential
hypertension rarely exists below the period of adolescence
and the incidence of secondary hypertension, without significant comorbidity, is extremely low. Failure to consider
these age-related differences can negatively impact overall
enrollment and the balance of enrollment across the various
age cohorts. Worse, the study may be so slow to enroll that
it exceeds planned time frames, adds costs, or terminates
prior to completion. Familiarity with the population you are
attempting to engage in a critical trial, including their usual
patterns of care, is essential to the success of the trial.
Recruitment and enrollment
In a recent review of pediatric clinical trials registered on
ClinicalTrials.gov, 19% were terminated early, largely because of difficulty with patient accrual.4 The timing of your
study is extremely relevant to its success, with respect to
enrollment and retention of pediatric participants. For example, a PK study that requires more than a 4-hour sampling period will be very slow to enroll during the academic
year, as parents/children are unwilling to miss school.
Clinical and Translational Science

Conducting such studies during the summer months or
during school breaks, when children are already out of
school, is incredibly helpful, in our experience. Similarly,
being prepared to schedule study visits on holidays and
weekends greatly improves pediatric enrollment, as parents are, generally, not challenged by the demands of work
or providing child care.
Thoughtful evaluation of research protocol fasting and
resting requirements is equally important to optimizing
study enrollment by minimizing the disruption to a child’s/
parent’s daily schedule. In our experience, studies that
require extensive fasting or resting (e.g., > 2–4 hours) are
best conducted in the morning, or after nap t ime, depending on the child’s age, when children are naturally fasted
and have not yet had a chance to exert themselves with
play or other physical activity. Restricting intake of certain foods (e.g., caffeine-containing soft drinks, chocolate,
milk, and fruit juices) for prolonged periods of time (e.g.,
days) prior to the study visit can present significant challenges during the school year, when children are receiving
school meals, and it may not be feasible, or practical, for
parents to modify their child’s diet to accommodate a research requirement.
We experience these “expected” pediatric challenges
when engaging healthy children; however, studies that target enrollment of otherwise healthy children are generally
limited to medications from which the child may benefit,
or be reasonably exposed to, during the course of his/her
normal “healthy” childhood (e.g., antibiotics, cough/cold
products, etc.). In reality, most investigations are looking to
identify and enroll children with specific disease processes.
For children with diabetes, attention deficit/hyperactivity
disorder (ADHD), or inflammatory bowel disease, investigators need to consider the impact of disease on the participants’ and the family’s daily living and design a protocol that
is minimally disruptive to their quality of life.
When these same patients are participating in your study
at a clinical research unit, investigators must consider
whether the facility is equipped with the necessary supplies
to make the study visit a successful and enjoyable experience for the child. A diabetes trial that requires excessively
frequent finger sticks (we have seen > 20 over an 8-hour
period proposed in one investigation) will not be pleasant
for the participant. Similarly, confinement of a patient with
ADHD to a study unit that does not have a sufficient array of
activities to occupy the child will have even the most experienced research team frazzled by day’s end. In the example
of ADHD, investigators should have a plan in place with the
research team, the child life department, volunteer services,
or the family to ensure the availability of age-specific and
gender-specific opportunities that the child will find engaging. Providing this extra service, and addressing it at the
time of recruitment, may help patients and families decide
whether or not they would like to participate in the trial. A
brief tour of the research unit at the time of study recruitment
can be very reassuring for a child/family, as is an introduction to the key members of the study team who will be conducting the study visit.
Approaching potential study participants as a team with
both the principal investigator and the research coordinator
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present can be to the study team’s advantage. Generally,
the principal investigator can better address the scientific
focus of the investigation, whereas the coordinator can
speak best to the actual breakdown of the study visit.
Explaining study procedures in terms age a
 ppropriate and
understandable for the child as well as the parent is essential for their engagement in research. We find the use of
props for demonstration of common research procedures,
such as i.v. catheter starts, tremendously helpful. We also
always remind participants that once the i.v. goes in, the
needle does not stay in them (a common pediatric fear);
rather, what remains is “a bendy, plastic straw,” which we
always show to them and let them examine. The number
of fears we have alleviated with this simple technique is
innumerable.

As with any human subject research, all efforts should be
made to minimize the risks to the pediatric participant. When
obtaining informed consent/assent for pediatric research, it
is important to remember that research risks constitute any
and all harms, discomforts, indignities, embarrassments,
and potential breaches of privacy/confidentiality associated
with research, and this must be explained not only to the
parents/guardians but also to children of assent age, using
age-appropriate terminology that they can understand. In
our experience, illustrated research consent/assent forms
are very useful for engaging participants and can be very
helpful to facilitate age-appropriate dialogue. Notably, parents/guardians also see the value of creatively modified consent forms, and, when thoughtfully constructed, IRBs are
very willing to consider abbreviated-illustrated documents in
lieu of longer text-based forms.45

RESEARCH ETHICS
Historically, there has been some reluctance to involve children
in clinical trials due to fear of exposing children to harm from
previously untested, equivocal treatments;3 however, tragic examples of what can happen when treatments not investigated
in children are prescribed to children (e.g., gray baby syndrome
from chloramphenicol41) highlight the importance of including
children in clinical trials, especially when children comprise a
portion of the targeted treatment population. In 1989, the right
of children to enjoy the highest attainable standard of health,
including the right to have research evidence for treatments
commonly used in children, was formally recognized by the
United Nations Convention on the Right of the Child.3
Informed consent and assent
Similar to other types of human subject research, pediatric research is protected by The Nuremberg Code and
requires informed consent for research participation.3,42,43
However, informed consent for participation in pediatric
trials is more complex than adult trials because informed
consent is granted by proxy, from a parent or legal guardian
responsible for protecting the welfare of the child, in accordance with the Declaration of Helsinki.3,42,43 In the United
States, pediatric research involving minimal risk or direct
potential benefit to the child requires signature from one
parent/guardian, whereas all other risk categories of pediatric research, as determined by the IRB, require signatures
from both parents/guardians.42 Specifically, Subpart D of
the Common Rule (Protection of Human Subjects, 45 Code
of Federal Regulations (CFR) 46) stipulates that studies involving greater than minimal risk and no direct benefit to the
child are generally not allowed, unless they (i) are likely to
yield generalizable knowledge about the participant’s condition or (ii) present an opportunity to understand, prevent,
or alleviate a serious problem affecting the health/welfare
of children;44 however, interpretation of these stipulations
resides with the IRB.
In addition to parental/guardian permission (i.e., research
consent), informed assent (or dissent) to participate in research also needs to be obtained from the child.42 Barring
any special circumstances regarding the child’s cognitive
abilities, 7 years of age is generally considered the age of
assent by most institutions.42

Payment for participation
Payment for participation in pediatric research is allowed
in the United States and parts of Europe, although different
IRBs may have different stipulations with respect to payment type (i.e., reimbursement, compensation, incentive,
or appreciation46) and payment value. In our experience,
to avoid undue influence while still demonstrating appreciation for study engagement, the payment type and value
ought to reflect the effort and commitment required on the
part of the study participant first and the parent/guardian
second.
Monitoring and safety
When it comes to safety and data monitoring, studies
conducted in children are subject to the same regulatory
requirements as adult investigations.5,42,47 Drug safety assessments are paramount to pediatric trials, as even the
complete efficacy extrapolation approach endorsed by the
FDA (option C in the FDA Pediatric Study Decision Tree from
the Office of Pediatric Therapeutics; Figure 3) requires the
collection of safety data in children.48 At a minimum, all trials should have a clear data safety and monitoring plan,
which can be augmented by a formal data safety and monitoring board that convenes at regular intervals to assess
data integrity, protocol deviations/violations, subject withdrawals, study hold or stopping rules, and any other applicable issues.
RESEARCH INFRASTRUCTURE
The success of a clinical trial not only depends on thoughtful
and age-appropriate study design but also on accessibility
to appropriate research facilities to conduct the research.
The “right place” for conducting pediatric research encompasses considerations that include the physical space, the
professional staff, and a research infrastructure (e.g., IRB,
human subjects protection program, professional research
education/training) that has the wellbeing of the child at
the center of its mission focus and a dedication to creating
a safe and positive learning environment at the forefront
of its operations.49 Institutions driven by a mission that
embraces the core principles of safety, teamwork, compassion, and excellence create the potential for an ideal
www.cts-journal.com
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Figure 3 Extrapolation in pediatric drug development, decision tree from the US Food and Drug Administration; image borrowed from
https://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm106614.htm,47 public domain.

environment for developing and supporting a successful
pediatric clinical trial program. Although, arguably, these
core facets are also required of institutions where adult trials are conducted, it is their orientation toward the unique
challenges (and opportunities) of pediatrics, encompassing care for infants, children, and adolescents, that makes
them distinct.
For example, it is essential that the members of the IRB
and professionals who are part of the research administrative infrastructure (e.g., attorneys, grant accountants,
pre-award and post-award grant/contract specialists) have
appropriate knowledge and understanding of the unique
federal regulations that impact the study of drugs and devices in infants and children. Clinical research professionals (e.g., investigators, research coordinators, nurses, and
laboratory technicians) must understand both the regulatory
requirements unique to pediatrics and how the intersection
of human development and disease (both expression and
course) influence the ability to conduct a clinical trial with
minimal disruption to the child’s medical and psychosocial
needs or the family’s daily routine. Finally, the physical environment of the facility where research is to be conducted
is critical to the success of the investigation. As recently
described, the look, feel, and function of the research facility must be “kid savvy” by creating an environment that
Clinical and Translational Science

is inviting and safe, not threatening, for pediatric patients
and their families.50 These accommodating and reassuring
features should extend to specialized hospital research units
that are designed primarily for conducting nontherapeutic
research in subpopulations of infants and children who have
a specific medical condition.
Utilizing established networks and research
organizations
Established pediatric networks can offer solutions to many
of the challenges of conducting pediatric clinical trials. One
example of such an organization, well familiar to the authors, is the Eunice Kennedy Shriver National Institute of
Child Health and Human Development–funded Pediatric
Trials Network (PTN).
Established under the auspices of the Best Pharmaceuti
cals for Children Act in 2010, the PTN is an alliance of research sites, therapeutic area experts, and thought leaders
in key facets of pediatric trials51 that offer research support
to new and established investigators. Similar to other pediatric research networks, the PTN strives for excellence in
five key components of clinical trials: (i) protocol design and
development; (ii) site management and education; (iii) study
implementation and execution; (iv) data analysis and interpretation; and (v) regulatory affairs.
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Protocol design and development in the PTN is a multidisciplinary and interactive process involving all network
stakeholders. By promoting collaboration between clinical
therapeutic area experts and thought leaders in clinical trial
methodology, innovative protocols that efficiently and safely
fill critical knowledge gaps are designed. Examples of protocols designed through collaboration with the PTN include
the largest pediatric opportunistic multidrug PK and safety
study (POP01), a multidrug study of maternal–infant drug
transmission through breast milk (BMS01), and the first ever
long-term safety study of antipsychotics in children and adolescents (LAP01).
Site management in the PTN is performed in collaboration
with the Data Coordinating Center, which offers education
and support to participating study sites and helps investigators identify appropriate study sites for their investigation.
Site selection is a multistep process, involving network-wide
and study-specific questionnaires, individual site contacts,
and review of prior performance metrics. Sites are trained and
supported throughout the study by actively engaged study
investigators and operational personnel. High-enrolling sites
are routinely rewarded with coauthorship on study-derived
publications, and study data are made publicly available for
secondary analysis to investigators after study completion.
Study implementation and execution is overseen by a
core team of faculty and operational staff. Such teams
support sites through educational materials and manuals of study procedures, scheduled study calls, and ad
hoc consultation for study-related issues. Monitoring and
safety, facilitated by the team, is risk based and includes
remote and in-person site visits, conducted by the Data
Coordinating Center.
Data analysis and interpretation is facilitated by experts
in biostatistics, PK/PD modeling, clinical pharmacology, and

other fields at multiple academic institutions in the United
States and worldwide, brought together under the network’s
umbrella. After completion of the primary end-point analysis,
trial data are quickly and easily made accessible to the public to promote the conduct of secondary analyses.
Regulatory rigor is ensured and maintained by the network, with investigators and regulatory scientists involved in
all key phases of the study. For example, all PTN studies are
conducted under an FDA Investigational New Drug application. Study databases are 21 CFR compliant and data analysis facilities, including biological laboratories, are routinely
reviewed by Quality Assurance/Quality Control teams, facilitating submission of study results to regulatory bodies (e.g.,
the FDA) to support potential label change negotiations with
drug label holders. Thus, new and established investigators
are offered an opportunity to learn relevant regulatory elements of conducting pediatric trials, with appropriate oversight and guidance from the network.
Network leadership is committed to training the next generation of pediatric clinical trialists by allowing junior scientists from across network sites to support and/or lead PTN
trials, under the mentorship of a senior trialist. Scientists are
encouraged to submit study proposals via a brief and easyto-complete sheet, available on the network’s website (www.
pediatrictrials.org), which also provides a rapid online survey
to encourage participation of new study sites. Although the
authors are most familiar with the PTN, similar qualified research networks and organizations are available as valuable
resources to investigators around the globe (Table 2).
HELPFUL HINTS
Taking under advisement the practical considerations,
combined research experiences, and support systems

Table 2 Select examples of resources available to investigators through established research networks and organizations across the globe
Resource
Pediatric Trials Network

Region

Information link

USA

www.pediatrictrials.org52
https://c-path.org/programs/ptc/53

Critical Path Institute-Pediatric Trials
Consortium
Guidance from the FDA

https://www.fda.gov/ScienceResearch/SpecialTopics/
PediatricTherapeuticsResearch/default.htm54
https://www.fda.gov/downloads/drugs/guidances/
ucm425885.pdf55
https://www.fda.gov/downloads/drugs/guidances/
ucm360507.pdf56

EMA

Europe

https://www.ema.europa.eu/en/human-regulatory/research-
development/paediatric-medicines/
paediatric-clinical-trials57

Canadian Institutes of Health Research-
Institute of Human Development, Child
and Youth Health

Canada

http://www.cihr-irsc.gc.ca58

World Health Organization-International
Clinical Trials Registry Platform

International

https://www.who.int/ictrp/child/en/59

Guidance from the International
Conference on Harmonization

https://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Efficacy/E11/Step4/E11_Guideline.
pdf60
https://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Efficacy/E11/E11-R1EWG_Step4_
Addendum_2017_0818.pdf61

EMA, European Medicines Agency; FDA, US Food and Drug Administration.
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Study Drug
Decide on dosing scheme (fixed dose vs. weight/size-based dosing)
Determine if the formulation age appropriate
-

Most children are physiologically mature to swallow pills by age 7 years

-

Consider formulation effect, especially if compounding or using multiple formulations

-

Consider palatability

-

Consider food effect, if drug co-administered with anything other than water (e.g., juice)

PK
relevant to the disposition of the study drug
Consider impact of developmental alterations in physiology on drug disposition
-

Especially relevant for neonates, infants, and young children(e.g., relative achlorhydria of neonatal
stomach and drug dissolution)

-

PK sampling scheme should capture anticipated age-related differences in drug absorption, Vd and
CL, compared with adult data

If a PK/PD relationship can be extrapolated from adult data, use that knowledge to design your PK
sampling strategy
Do not exceed maximum allowable blood volumes for PK sampling
-

Volumes based on age and weight, and represent total blood drawn for clinical and research
purposes combined, over a specified time frame (check with your IRB for exact volumes)

During analysis, PK parameters may need to be normalized for weight/size for comparisons
PD

-

If no, a new PD measure may need to be developed and validated in children

Safety data must be collected, even if using the complete efficacy extrapolation approach endorsed by
the FDA
-

Establish a data safety and monitoring plan

Figure 4 Checklist of key elements for successful pediatric clinical trial design and execution; pharmacokinetics (PKs),
pharmacodynamics (PDs). CFR, Code of Federal Regulations; DME, drug metabolizing enzyme; FDA, US Food and Drug Administration;
IRB, institutional review board; PTN, Pediatric Trials Network.
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Study Population
Confirm that the condition being studied occurs in all ages proposed for study (e.g., essential
hypertension almost never affects young children, but is increasingly recognized in adolescents)
Confirm that the proposed study site has access to the patient population being studied
If the study spans age groups, define groups based on chronological age vs. maturity rating (e.g.,
Tanner Staging)
Ensure that all study equipment is age and size appropriate (e.g., pediatric vs. adult blood pressure
cuffs for vital signs)
Minimize fear/pain from invasive procedures (e.g., IV insertion)
-

Use child-friendly language and distraction techniques (consult child life services, if available)

-

Use props to demonstrate study procedures and allow children to examine study equipment, if
possible

Provide age appropriate resources and activities for children participating in longer studies (e.g., 4 hours)
-

Consult child life services for availability of age appropriate activities at the study site

-

Consider partnering with qualified volunteers (e.g., trainees, students) to provide age-appropriate
activities during study visits

Decide if you will pay participants for their time and effort
Study Timing
Minimize disruption to school schedule
-

Consider offering study visits on holidays, weekends, evenings

-

Target school breaks (e.g., summer) for high enrollment, especially if study requires longer visits
(e.g., 4 hours)

Give careful consideration to fasting/resting requirements, especially for younger children
Figure 4 Continued

outlined in this tutorial, you should feel empowered to take
on a pediatric clinical trial at your institution, but before you
enroll your first research participant, pause and implement
a mock trial run.
Mock trial run
The dogma in research coordinator training clearly states
that the data collected on the first study participant will

almost certainly be discarded. To avoid this common pitfall, always perform a mock run of the study visit, from
consent/assent to post-study follow-up telephone call. A
mock run of your investigation, in the actual physical space
where the investigation will take place, allows you to assess
the study flow, enabling you to identify unforeseen gaps
in study logistics/procedures before you enroll your first
patient. We have captured, and corrected, oversights in
www.cts-journal.com
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Informed Consent/Assent
Discuss study risk category, based on the Common Rule (Protection of Human Subjects, 45 CFR 4644),
with your IRB
-

Single parent/guardian consent and signature if study is no more than minimal risk or is of direct
benefit to the child

-

All other studies require consent and signatures from both parents/guardians

Child assent usually applicable for children >7 years (check with your IRB for exact age)
Use written and verbal language that is understandable to both the parent/guardian and the child
-

Consider using an illustrated consent/assent document

Logistics
Consider using established research networks as a source for information, consultation, trial execution,
and/or funding (e.g., PTN; www.pediatrictrials.org)
Solicit feedback regarding study feasibility and design from clinicians familiar with the condition/patient
population being studied, as well as from patients and parents
-

Focus groups can be helpful

Conduct a mock study visit prior to enrolling your 1 st study participant
Allow extra time between the 1st and 2nd research participant to allow for feedback and troubleshooting
-

Ask the participant, parent, and research coordinator how it wentand address any issues/concerns

before enrolling the next participant
Figure 4 Continued

case report forms, feasibility of time-sensitive study steps
(e.g., travel time for getting biologic specimens to and from
a processing laboratory), availability of equipment (e.g.,
age-appropriate blood pressure cuffs, centrifuges, and examination rooms), and/or ancillary staff (e.g., pharmacy dispensing services), particularly relevant if research facilities
are shared among investigators or compete for resources
with clinical services.
In addition, a trial run ensures consistency in informed
consent/assent language used by different members of the
study team and confirms that research procedures do not
interfere with clinic flow. If any research procedures (e.g.,
patient recruitment in a busy clinic, timing of the research
consent/assent, utilization of clinic examination rooms to
Clinical and Translational Science

confirm study inclusion/exclusion criteria, etc.), even tangentially, encroach on patient care, we recommend an open
discussion with the clinical team to look for compromises
and solutions. Performing this exercise of a mock trial allows
you to make any necessary changes to the protocol, or the
manual of operations, before you start collecting precious
real data for your investigation.
We also recommend allowing a small time buffer, after
the enrollment of your first research participant, to adjust
any research procedures (if needed) not captured by the
trial run. This approach negates the need for rescheduling
subsequent participants if any unforeseen circumstances
are encountered during the research experience of your first
study participant.
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Research engagement
Whether you are implementing your first or your 100th clinical trial, to build a culture of research at your institution,
engage your colleagues and your study participants in the
research you are conducting. Identification of potential
study participants by ancillary staff, nurses, and clinicians
increases if they understand the scientific merit of your clinical trial and its value to children. Do not underestimate the
altruism of children and families when they fully understand
the future implications (both risks and benefits) of the knowledge they help generate through voluntary participation in
research. Finally, make every effort to periodically update
your colleagues, research staff, and research participants
(to the extent permitted by the study protocol) regarding
your study progress and interim data analysis. There is
nothing more rewarding than seeing the smile on a child’s
face when they hear that the research study they participated in was published in a scientific journal, cited on social media, or helped to make a difference for another child.
We have successfully used printouts of our featured studies
from the PTN website, for example, to update research participants on their contribution to science when they return to
the clinic for routine care or to our research unit for another
clinical trial. Sharing the outcomes of your clinical trial with
the community creates a culture of trust and mutual respect
for future research participation at your institution.
CONCLUSIONS
In summary, extensive prestudy planning, designed to establish a thorough understanding of the developmental differences in physiology that differentiate the stages of human
growth and development from birth to adulthood, their impact
on PK and PD, and your study team’s ability to accommodate
these dynamic changes, is key to successfully implementing a pediatric clinical trial at your institution. Although the
study planning process may seem daunting, resources are
available to help you. Guidelines are available from regulatory
agencies (e.g., the FDA and EMA) regarding PK/PD extrapolations, support from established networks (e.g., PTN) for
financial and practical considerations, and education from
seasoned trialists and coordinators to help you avoid common pitfalls and fatal mistakes (Figure 4). Equally important are solicitations of feedback and input from your local
IRB, clinical colleagues who are familiar with the medical and
psychosocial nuances of the pediatric population you are
targeting for study participation, and the patient population
(children and parents) you are trying to engage in research.
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